Chiara Greco
Development of Pyrazolo[3,4- d]pyrimidine Kinase Inhibitors as Potential Clinical Candidates for Glioblastoma Multiforme
Greco, Chiara; Taresco, Vincenzo; Pearce, Amanda K.; Vasey, Catherine E.; Smith, Stuart; Rahman, Ruman; Alexander, Cameron; Cavanagh, Robert J.; Musumeci, Francesca; Schenone, Silvia
Authors
Dr VINCENZO TARESCO VINCENZO.TARESCO@NOTTINGHAM.AC.UK
NOTTINGHAM RESEARCH FELLOW
Amanda K. Pearce
Catherine E. Vasey
Dr STUART SMITH stuart.smith@nottingham.ac.uk
CLINICAL ASSOCIATE PROFESSOR
Professor Ruman Rahman RUMAN.RAHMAN@NOTTINGHAM.AC.UK
PROFESSOR OF MOLECULAR NEURO-ONCOLOGY
Professor CAMERON ALEXANDER CAMERON.ALEXANDER@NOTTINGHAM.AC.UK
PROFESSOR OF POLYMER THERAPEUTICS
Robert J. Cavanagh
Francesca Musumeci
Silvia Schenone
Abstract
Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor. Residual cells at the tumor margin are responsible for up to 85% of GBM recurrences after standard treatment. Despite this evidence, the identification of compounds active on this cell population is still an underexplored field. Herein, starting from the knowledge that kinases are implicated in GBM, we evaluated three in-house pyrazolo[3,4-d]pyrimidines active as Src, Fyn, and SGK1 kinase inhibitors against patient derived cell lines from either the invasive region or contrast-enhanced core of GBM. We identified our Src inhibitor, SI306, as a promising lead compound for eradicating invasive GBM cells. Furthermore, aiming at the development of a feasible oral treatment for GBM, we performed a formulation study using 2D inkjet printing to generate soluble polymer-drug dispersions. Overall, this study led to the identification of a set of polymer-formulated pyrazolo[3,4-d]pyrimidine kinase inhibitors as promising candidates for GBM preclinical efficacy studies.
Citation
Greco, C., Taresco, V., Pearce, A. K., Vasey, C. E., Smith, S., Rahman, R., Alexander, C., Cavanagh, R. J., Musumeci, F., & Schenone, S. (2020). Development of Pyrazolo[3,4- d]pyrimidine Kinase Inhibitors as Potential Clinical Candidates for Glioblastoma Multiforme. ACS Medicinal Chemistry Letters, 11(5), 657-663. https://doi.org/10.1021/acsmedchemlett.9b00530
Journal Article Type | Article |
---|---|
Acceptance Date | Feb 13, 2020 |
Online Publication Date | Feb 19, 2020 |
Publication Date | May 14, 2020 |
Deposit Date | Mar 4, 2022 |
Publicly Available Date | Mar 7, 2022 |
Journal | ACS Medicinal Chemistry Letters |
Electronic ISSN | 1948-5875 |
Publisher | American Chemical Society |
Peer Reviewed | Peer Reviewed |
Volume | 11 |
Issue | 5 |
Pages | 657-663 |
DOI | https://doi.org/10.1021/acsmedchemlett.9b00530 |
Public URL | https://nottingham-repository.worktribe.com/output/4007035 |
Publisher URL | https://pubs.acs.org/doi/10.1021/acsmedchemlett.9b00530 |
Files
Development Of Pyrazolo 3 4-d Pyrimidine Kinase Inhibitors As Potential Clinical Candidates For Glioblastoma Multiforme 2020
(2.1 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
You might also like
Radiogenomics as an Integrated Approach to Glioblastoma Precision Medicine
(2024)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search